UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________to _____________ Commission File Number: 001-39015 BIOVIE INC. (Exact name of registrant as specified in its charter) Nevada 46-2510769 (State or ot ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government. S ...

Increasing evidence supports a role for viral persistence, chronic inflammation and immune and metabolic dysregulation in driving long COVID Bezisterim, an anti-inflammatory and insulin-sensitizer that permeates the blood brain barrier, could represent a novel oral treatment targeting an underlying cause of long COVID symptoms CARSON CITY, Nev., April 29, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the tre ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

Bezisterim的研究结果 - "Bezisterim"已被批准为NE3107的非专有名称，可能通过与与老年痴呆症、新陈代谢和炎症相关的特定基因来恢复稳态[1] - Bezisterim在患有轻度至中度可能老年痴呆症的受试者中的临床结果和生物标志物发现的展示[2] - Bezisterim的能力降低DNA甲基化似乎针对迄今已确定的21个特定基因[4]

CARSON CITY, Nev., April 18, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that an oral presentation and poster presentation will be shared at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit to be held in Boston, Massachusetts April 23-25. Additionally, the United States Adopted Names ( ...

股价走势 - BioVie Inc. (BIVI)最近的股价走势呈现熊市，过去一周股价下跌了34.8%[1] - BIVI近期的盈利预期修订呈上升趋势，这是基本面上的一个积极指标，与近期股价走势密切相关[7] - 过去30天，BIVI今年的每股收益预期共同增长了12.3%，这表明分析师普遍认为公司将报告比之前预测更好的盈利[8] Hammer图形模式 - Hammer图形模式的形成表明股票可能很快出现趋势反转，因为多头可能已经对价格获得了重要控制，帮助其找到支撑[1] - Hammer图形是蜡烛图中的一种常见价格模式，其在下跌趋势中形成，表明熊方通常控制着股票，但在找到支撑后，买盘兴趣出现，推动股价上涨[3] - Hammer蜡烛可以出现在任何时间框架上，被短期和长期投资者使用[5] - Hammer图形模式虽然有其局限性，但应始终与其他多头指标结合使用[6] Zacks排名 - BIVI目前的Zacks排名为2（买入），这意味着它在我们基于盈利预期修订和每股收益惊喜趋势排名的4000多支股票中处于前20%[9]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

Recently completed financing provides sufficient funds for near-term Parkinson's Disease priority Plans for Phase 2b trial of NE3107 as first-line monotherapy for Parkinson's Disease being finalized with targeted launch late-summer 2024 Once-daily NE3107 formulation expected to be available early 2025 and will be used for Phase 3 trial in Alzheimer's Disease Phase 3 trial for BIV201 in preparation following FDA feedback with guidance on development path; program delayed pending partnership funding CARSON CI ...

CARSON CITY, Nev., March 06, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of its previously announced best efforts public offering of 15,000,000 shares of its common stock, pre- funded warrants to purchase 6,000,000 shares of its common stock ("Pre-funded Warrants")and ...